Bracke A, Van Elzen R, Van der Veken P, Augustyns K, De Meester I, Lambeir AM (2019) <br />The development and validation of a combined kinetic fluorometric activity assay for fibroblast activation protein alpha and prolyl oligopeptidase in plasma<br /><i>Clinica Chimica Acta</i> <b>495</b>: 154<br /><br />Rea D, Van Elzen R, De Winter H, Van Goethem S, Landuyt B, Luyten W, Schoofs L, Van der Veken P, Augustyns K, De Meester I, Fulop V, Lambeir AM (2017) <br />Crystal structure of Porphyromonas gingivalis dipeptidyl peptidase 4 and structure-activity relationships based on inhibitor profiling<br /><i>Eur Journal of Medicinal Chemistry</i> <b>139</b>: 482<br /><br />Van Elzen R, Schoenmakers E, Brandt I, Van der Veken P, Lambeir AM (2017) <br />Ligand-induced conformational changes in prolyl oligopeptidase: a kinetic approach<br /><i>Protein Engineering Des Sel</i> <b>30</b>: 217<br /><br />Jaako K, Waniek A, Parik K, Klimaviciusa L, Aonurm-Helm A, Noortoots A, Anier K, Van Elzen R, Gerard M, Lambeir AM, Rossner S, Morawski M, Zharkovsky A (2016) <br />Prolyl endopeptidase is involved in the degradation of neural cell adhesion molecules in vitro<br /><i>Journal of Cell Science</i> <b>129</b>: 3792<br /><br />Kehoe K, Van Elzen R, Verkerk R, Sim Y, Van der Veken P, Lambeir AM, De Meester I (2016) <br />Prolyl carboxypeptidase purified from human placenta: its characterization and identification as an apelin-cleaving enzyme<br /><i>Biochimica & Biophysica Acta</i> <b>1864</b>: 1481<br /><br />Klimaviciusa L, Jain RK, Jaako K, Van Elzen R, Gerard M, Van der Veken P, Lambeir AM, Zharkovsky A (2012) <br />In situ prolyl oligopeptidase activity assay in neural cell cultures<br /><i>Journal of Neuroscience Methodsods</i> <b>204</b>: 104<br /><br />Myohanen TT, Hannula MJ, Van Elzen R, Gerard M, Van der Veken P, Garcia-Horsman JA, Baekelandt V, Mannisto PT, Lambeir AM (2012) <br />A prolyl oligopeptidase inhibitor, KYP-2047, reduces alpha-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease<br /><i>British Journal of Pharmacology</i> <b>166</b>: 1097<br /><br />Van der Veken P, Fulop V, Rea D, Gerard M, Van Elzen R, Joossens J, Cheng JD, Baekelandt V, De Meester I, Lambeir AM, Augustyns K (2012) <br />P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy<br /><i>Journal of Medicinal Chemistry</i> <b>55</b>: 9856<br /><br />Van Elzen R, Lambeir AM (2011) <br />Structure and function relationship in prolyl oligopeptidase<br /><i>CNS Neurol Disord Drug Targets</i> <b>10</b>: 297<br /><br />